Table 3.
Group | Volume | Slope (γ50) | EQD2 | |
---|---|---|---|---|
TD20 (Gy) | TD50 (Gy) | |||
Both hippocampi | 100% | 0.42 | 10.9 | 59.3 |
50% | 0.53 | 22.1 | 62.9 | |
0 | 0.55 | 37.0 | 101.4 | |
1 cc | 0.57 | 33.3 | 85.5 | |
Left hippocampus | 100% | 0.49 | 14.0 | 47.3 |
50% | 0.44 | 17.1 | 78.4 | |
0 | 0.45 | 23.7 | 101.7 | |
0.5 cc | 0.42 | 18.4 | 100.4 | |
Right hippocampus | 100% | 0.52 | 19.3 | 57.2 |
50% | 0.51 | 24.1 | 75.2 | |
0 | 0.48 | 28.8 | 105.1 | |
0.5 cc | 0.49 | 25.9 | 90.0 |
TDX: tolerated dose (EQD2) resulting in X% risk of HVLT-R DR decline in 6 months.
The slope parameter (γ50) of the dose–response curve in the logistic normal-tissue complication probability (NTCP) model without volume effect is calculated at TD50.